Cambridge Healthtech Institute’s 4th Annual
Gene Therapy Manufacturing
( 基因療法藥物的製造 )
Production Strategies for Vector-Based Gene Therapies
It is an exciting time for gene therapy – therapies on the market, strong investment and encouraging clinical data – but manufacturing still represents one of the major stumbling blocks to successful commercialization.
Cambridge Healthtech Institute’s Gene Therapy Manufacturing conference takes a practical, case-study driven approach to the process development, scale-up and production of gene therapies, tackling key topics such as AAV, lentivirus and retrovirus process development and scale-up, CMO management from early to late-stage development.
PROCESS DEVELOPMENT STRATEGIES FOR AAV GENE THERAPIES
KEYNOTE PRESENTATION: Present and Future of AAV Gene Therapy Technical Development and Manufacturing
Luis Maranga, PhD, Chief Technical Operations Officer, Voyager Therapeutics, Inc.
FEATURED PRESENTATION: Development, Optimization and Technology Transfer of the Scalable Pro10TM rAAV Manufacturing Process
Josh Grieger, PhD, CTO, Asklepios BioPharmaceutical
rAAV Vector Design, Capsid Directed Evolution and Scale Up Activities Using the BEVS System
Jacek Lubelski, PhD, Vice President, Global Pharmaceutical Development, uniQure
AAV Process Development
Justin Horvath, PhD, Director, Manufacturing, Regenxbio
AAV Vectors: From Discovery to Large-Scale Clinical Manufacturing: An Academic Success Story
Nathalie Clément, PhD, Associate Director and Associate Professor, Powell Gene Therapy Center, Pediatrics, University of Florida
Optimization of Transfection and Culture Conditions to Maximize AAV Production in Suspension 293-Based Cells
Bryan Piras, PhD, Senior Scientist II, Process Development, Therapeutics Production and Quality, St. Jude Children’s Research Hospital
Development of an Advance AAV Purification Platform Using Integrated Analytics and PAT
Florian Leseigneur, PhD, Viral Vector Development Team, Cell and Gene Therapy Catapult
AAV Purification or Viral Clearance
Jason Morais, PhD, DSP Lead, Gene Therapy Development, Sanofi
Development of High-Throughput Purification Methods for AAV
Matthew Kevin Roach, PhD, Senior Associate Scientist, Gene Therapy Process Development, Pfizer
Scalable Suspension Process Development for Viral Vectors
Sven Ansorge, PhD, Research Officer, National Research Council Canada
Optimizing Viral Vector Manufacturing
Michael Greene, MD, Executive Director, Technology Transfer Lead, Mustang Bio, Inc.
Directed Development of Upstream Production Processes for AAV Vectors for Reduced Cost of Goods and Improved Manufacturing Fit
Terrence Dobrowsky, PhD, Principal Engineer, Gene Therapy, Biogen